Blood Cancer: Myths Vs Facts - Experts Bust 10 Common Misconceptions About Diagnosis, Risk & Treatment

  

Blood cancer, or hematologic malignancy, is often surrounded by misconceptions that delay diagnosis and treatment. From the belief that it’s always inherited or contagious, to myths around stem cell transplants and alternative cures, misinformation can cost precious time and hope. To bring clarity, Dr Chepsy C Philip, Clinical Hematology & Bone Marrow Transplant Physician at Believers Church Medical College Hospital, Thiruvalla, debunks the most common myths about blood cancer and shares the truth about how it can be detected, treated, and even cured with today’s advanced therapies. 

Myth 1: Blood cancer is always an inherited disease. 

Fact: While blood cancer results from acquired genetic changes, most cases are not inherited. Environmental exposures and random mutations are often the cause.  

Myth 2: Blood cancer affects older people 

Fact: Dr Philip says, "All age groups, including Children, young adults, and the elderly, are susceptible to blood cancer." 

Myth 3: Blood cancer spreads from person to person.
 
Fact: Blood cancer is not contagious, as it develops inside the body and poses no risk of being contagious.  

Myth 4: A Blood test is sufficient to detect blood cancer 

Fact: "Blood tests can show abnormalities, but a diagnosis often requires a bone marrow biopsy, imaging and gene testing," reveals Dr Philip.

Myth 5: You cannot have blood cancer if you look healthy. 

Fact: There are tendencies to overlook the common symptoms of blood cancers, such as persistent fatigue, unexplained weight loss, recurring fever, and night sweats. While such symptoms may not seem severe, preventive measures, such as routine blood tests, often help reveal the onset of the disease, allowing for early intervention in such cases. 

Myth 6: There is no hope once a patient is diagnosed with blood cancer. 

Fact: There are living examples worldwide where survivors have overcome or survived blood cancer. Advanced therapies, including immunotherapy, targeted therapy, CAR-T cells, and blood stem cell transplants, have improved survival rates and significantly enhanced the quality of life.  

Myth 7: Blood cancer can be cured with alternative medicine. 

Fact: Evidence-based therapies are beneficial in treating blood cancer. It is essential to note that alternative remedies may offer comfort but cannot replace medical treatments that are already proven to have better patient outcomes.  

Myth 8: Blood cancers spread quickly in all patients. 

Fact: Dr Philip says, "Not all types of blood cancer progress rapidly; for example, lymphoma may grow slowly and remain stable for years. Having said that, leukemia progresses rapidly. So it is not right to club all types of blood cancers to progress quickly in patients."

Myth 9: Blood cancer is just one disease. 

Fact: There are different types of blood cancer, including leukemia, lymphoma, and multiple myeloma. 

Myth 10: A blood stem cell transplant is risky and rarely successful. 

Fact: Blood stem cell transplants have enough evidence to potentially give someone with blood cancer and blood disorders a second chance at life. This treatment method has a proven track record, with success rates continually improving patient outcomes.  

 

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs

 

New Treatments for Multiple Myeloma

Multiple myeloma is a complex blood cancer characterized by the proliferation of malignant plasma cells within the bone marrow. Recent advancements in treatment have significantly improved patient outcomes, introducing innovative therapies that target the disease more precisely and effectively.

Traditional Treatment Approaches 

Historically, multiple myeloma has been managed through a combination of therapies: 

 

Chemotherapy: Utilizes cytotoxic drugs to kill rapidly dividing cancer cells. 

 

Corticosteroids: Help reduce inflammation and directly combat myeloma cells. 

 

Stem Cell Transplantation: Particularly autologous stem cell transplants (ASCT), where a patient's own stem cells are used to restore bone marrow function after high-dose chemotherapy. 

 

Radiation Therapy: Employed to control bone pain and treat localized disease.

Recent Advances in Treatment 

The past decade has witnessed remarkable progress in multiple myeloma treatment, with several novel therapies enhancing patient survival and quality of life: 

 

Proteasome Inhibitors: Drugs like bortezomib and carfilzomib disrupt cancer cell protein degradation, leading to cell death. 

 

Immunomodulatory Agents: Agents such as lenalidomide and pomalidomide modulate the immune system to target myeloma cells. 

 

Monoclonal Antibodies: Daratumumab and elotuzumab are designed to recognize and bind specific proteins on myeloma cells, marking them for destruction by the immune system. 

 

Recent promising developments: 

 

One notable advancement is the use of Blenrep (belantamab mafodotin), an antibody-drug conjugate targeting the B-cell maturation antigen (BCMA) on myeloma cells. Clinical trials have demonstrated that Blenrep, in combination with standard therapies like bortezomib and dexamethasone, can significantly reduce the risk of disease progression or death in patients with relapsed or refractory multiple myeloma. For instance, a recent study reported a 42% reduction in the risk of death when Blenrep was added to the treatment regimen. 

 

Another promising development is the approval of Elrexfio (elranatamab), a bispecific antibody that engages T-cells to target and destroy myeloma cells. Studies have shown that Elrexfio provides a median overall survival of more than two years in patients with relapsed or refractory multiple myeloma, highlighting its potential as an effective treatment option. 

 

Additionally, CAR T-cell therapies have emerged as a transformative approach in multiple myeloma treatment. These therapies involve modifying a patient's own T-cells to express chimeric antigen receptors (CARs) that specifically target myeloma cells. For example, Carvykti (ciltacabtagene autoleucel) has shown a 45% reduction in the risk of death in clinical studies, offering a one-time treatment alternative to ongoing drug regimens. 

 

These advancements underscore a dynamic shift in multiple myeloma treatment, with ongoing research poised to enhance patient outcomes and quality of life.

 

Prognosis and Conclusion 

The prognosis for multiple myeloma has improved significantly over the past decade, largely due to these therapeutic advancements. The overall five-year relative survival rate has increased to approximately 61.1%, with even better outcomes expected as new treatments continue to emerge. 

 

In conclusion, the landscape of multiple myeloma treatment is rapidly evolving, with recent developments offering renewed hope for patients. Ongoing research and clinical trials continue to explore innovative therapies and combination strategies, aiming to further improve survival rates and quality of life for those affected by this disease

 

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs

New Treatments for Multiple Myeloma

Multiple myeloma is a complex blood cancer characterized by the proliferation of malignant plasma cells within the bone marrow. Recent advancements in treatment have significantly improved patient outcomes, introducing innovative therapies that target the disease more precisely and effectively.

Traditional Treatment Approaches 

 

Historically, multiple myeloma has been managed through a combination of therapies: 

 

Chemotherapy: Utilizes cytotoxic drugs to kill rapidly dividing cancer cells. 

 

Corticosteroids: Help reduce inflammation and directly combat myeloma cells. 

 

Stem Cell Transplantation: Particularly autologous stem cell transplants (ASCT), where a patient's own stem cells are used to restore bone marrow function after high-dose chemotherapy. 

 

Radiation Therapy: Employed to control bone pain and treat localized disease.

Recent Advances in Treatment  

The past decade has witnessed remarkable progress in multiple myeloma treatment, with several novel therapies enhancing patient survival and quality of life: 

 

Proteasome Inhibitors: Drugs like bortezomib and carfilzomib disrupt cancer cell protein degradation, leading to cell death. 

 

Immunomodulatory Agents: Agents such as lenalidomide and pomalidomide modulate the immune system to target myeloma cells. 

 

Monoclonal Antibodies: Daratumumab and elotuzumab are designed to recognize and bind specific proteins on myeloma cells, marking them for destruction by the immune system.

Recent promising developments: 

One notable advancement is the use of Blenrep (belantamab mafodotin), an antibody-drug conjugate targeting the B-cell maturation antigen (BCMA) on myeloma cells. Clinical trials have demonstrated that Blenrep, in combination with standard therapies like bortezomib and dexamethasone, can significantly reduce the risk of disease progression or death in patients with relapsed or refractory multiple myeloma. For instance, a recent study reported a 42% reduction in the risk of death when Blenrep was added to the treatment regimen. 

 

Another promising development is the approval of Elrexfio (elranatamab), a bispecific antibody that engages T-cells to target and destroy myeloma cells. Studies have shown that Elrexfio provides a median overall survival of more than two years in patients with relapsed or refractory multiple myeloma, highlighting its potential as an effective treatment option. 

 

Additionally, CAR T-cell therapies have emerged as a transformative approach in multiple myeloma treatment. These therapies involve modifying a patient's own T-cells to express chimeric antigen receptors (CARs) that specifically target myeloma cells. For example, Carvykti (ciltacabtagene autoleucel) has shown a 45% reduction in the risk of death in clinical studies, offering a one-time treatment alternative to ongoing drug regimens. 

 

These advancements underscore a dynamic shift in multiple myeloma treatment, with ongoing research poised to enhance patient outcomes and quality of life.

Prognosis and Conclusion  

The prognosis for multiple myeloma has improved significantly over the past decade, largely due to these therapeutic advancements. The overall five-year relative survival rate has increased to approximately 61.1%, with even better outcomes expected as new treatments continue to emerge. 

 

In conclusion, the landscape of multiple myeloma treatment is rapidly evolving, with recent developments offering renewed hope for patients. Ongoing research and clinical trials continue to explore innovative therapies and combination strategies, aiming to further improve survival rates and quality of life for those affected by this disease.

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs

New Treatments for Multiple Myeloma

Multiple myeloma is a complex blood cancer characterized by the proliferation of malignant plasma cells within the bone marrow. Recent advancements in treatment have significantly improved patient outcomes, introducing innovative therapies that target the disease more precisely and effectively.

Traditional Treatment Approaches Historically, multiple myeloma has been managed through a combination of therapies: 

 

Chemotherapy: Utilizes cytotoxic drugs to kill rapidly dividing cancer cells. 

 

Corticosteroids: Help reduce inflammation and directly combat myeloma cells. 

 

Stem Cell Transplantation: Particularly autologous stem cell transplants (ASCT), where a patient's own stem cells are used to restore bone marrow function after high-dose chemotherapy. 

 

Radiation Therapy: Employed to control bone pain and treat localized disease.

Recent Advances in Treatment  

The past decade has witnessed remarkable progress in multiple myeloma treatment, with several novel therapies enhancing patient survival and quality of life: 

 

Proteasome Inhibitors: Drugs like bortezomib and carfilzomib disrupt cancer cell protein degradation, leading to cell death.

 

Immunomodulatory Agents: Agents such as lenalidomide and pomalidomide modulate the immune system to target myeloma cells. 

 

Monoclonal Antibodies: Daratumumab and elotuzumab are designed to recognize and bind specific proteins on myeloma cells, marking them for destruction by the immune system. 

 

Recent promising developments: 

 

One notable advancement is the use of Blenrep (belantamab mafodotin), an antibody-drug conjugate targeting the B-cell maturation antigen (BCMA) on myeloma cells. Clinical trials have demonstrated that Blenrep, in combination with standard therapies like bortezomib and dexamethasone, can significantly reduce the risk of disease progression or death in patients with relapsed or refractory multiple myeloma. For instance, a recent study reported a 42% reduction in the risk of death when Blenrep was added to the treatment regimen. 

 

Another promising development is the approval of Elrexfio (elranatamab), a bispecific antibody that engages T-cells to target and destroy myeloma cells. Studies have shown that Elrexfio provides a median overall survival of more than two years in patients with relapsed or refractory multiple myeloma, highlighting its potential as an effective treatment option. 

 

Additionally, CAR T-cell therapies have emerged as a transformative approach in multiple myeloma treatment. These therapies involve modifying a patient's own T-cells to express chimeric antigen receptors (CARs) that specifically target myeloma cells. For example, Carvykti (ciltacabtagene autoleucel) has shown a 45% reduction in the risk of death in clinical studies, offering a one-time treatment alternative to ongoing drug regimens. 

 

These advancements underscore a dynamic shift in multiple myeloma treatment, with ongoing research poised to enhance patient outcomes and quality of life.

Prognosis and Conclusion 

 

The prognosis for multiple myeloma has improved significantly over the past decade, largely due to these therapeutic advancements. The overall five-year relative survival rate has increased to approximately 61.1%, with even better outcomes expected as new treatments continue to emerge. 

 

In conclusion, the landscape of multiple myeloma treatment is rapidly evolving, with recent developments offering renewed hope for patients. Ongoing research and clinical trials continue to explore innovative therapies and combination strategies, aiming to further improve survival rates and quality of life for those affected by this disease

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.   

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement
https://cancersupportindia.blogspot.com  for infor on cancer and health related topics
https://GSiyers home remedies.blogspot.com   is the latest addition to my blogs. I'm going to add posts there, do give me your valuable feed back on my blogs. Thanks a lot, take care, be healthy and be happy.

Blood test accurately detects over 50 types of cancer, often before symptoms show

Researchers have developed the first blood test that can accurately detect more than 50 types of cancer and identify in which tissue the cancer originated, often before there are any clinical signs or symptoms of the disease.

In a paper published in the leading cancer journal Annals of Oncology [1] today (Tuesday) the researchers show that the test, which could eventually be used in national cancer screening programmes, has a 0.7% false positive rate for cancer detection, meaning that less than 1% of people would be wrongly identified as having cancer. As a comparison, about 10% of women are wrongly identified as having cancer in national breast cancer screening programmes, although this rate can be higher or lower depending on the number and frequency of screenings and the type of mammogram performed.

The test was able to predict the tissue in which the cancer originated in 96% of samples, and it was accurate in 93%.

Tumours shed DNA into the blood, and this contributes to what is known as cell-free DNA (cfDNA). However, as the cfDNA can come from other types of cells as well, it can be difficult to pinpoint cfDNA that comes from tumours. The blood test reported in this study analyses chemical changes to the DNA called "methylation" that usually control gene expression. Abnormal methylation patterns and the resulting changes in gene expression can contribute to tumour growth, so these signals in cfDNA have the potential to detect and localise cancer.

The blood test targets approximately one million of the 30 million methylation sites in the human genome. A machine learning classifier (an algorithm) was used to predict the presence of cancer and the type of cancer based on the patterns of methylation in the cfDNA shed by tumours. The classifier was trained using a methylation database of cancer and non-cancer signals in cfDNA. The database is believed to be the largest in the world and is owned by the company involved in this research, GRAIL, Inc. (California, USA).

Senior author of the paper, Dr Michael Seiden (MD, PhD), President of US Oncology (Texas, USA), said: "Our earlier research showed that the methylation approach outperformed both whole genome and targeted sequencing in the detection of multiple deadly cancer types across all clinical stages, and in identifying the tissue of origin. It also allowed us to identify the most informative regions of the genome, which are now targeted by the refined methylation test that is reported in this paper."

In the part of the Circulating Cell-free Genome Atlas (CCGA) study reported today, blood samples from 6,689 participants with previously untreated cancer (2482 patients) and without cancer (4207 patients) from North America were divided into a training set and a validation set. Of these, results from 4316 participants were available for analysis: 3052 in the training set (1531 with cancer, 1521 without cancer) and 1264 in the validation set (654 with cancer and 610 without cancer). Over 50 types of cancer were included.

The machine learning classifier analysed blood samples from the participants to identify methylation changes and to classify the samples as cancer or non-cancer, and to identify the tissue of origin.

The researchers found that the classifier's performance was consistent in both the training and validation sets, with a false positive rate of 0.7% in the validation set.

The classifier's ability to correctly identify when cancer was present (the true positive rate) was also consistent between the two sets. In 12 types of cancer that are often the most deadly (anal, bladder, bowel, esophageal, stomach, head and neck, liver and bile duct, lung, ovarian and pancreatic cancers, lymphoma, and cancers of white blood cells such as multiple myeloma), the true positive rate was 67.3% across clinical stages I, II and III. These 12 cancers account for about 63% of cancer deaths each year in the USA and, at present, there is no way of screening for the majority of them before symptoms show. The true positive rate was 43.9% for all cancer types in the study across the three clinical stages.

Detection improved with each cancer stage. In the 12 pre-specified cancers, the true positive rate was 39% in stage I, 69% in stage II, 83% in stage III and 92% in stage IV. In all of more than 50 cancer types, the corresponding rates were 18%, 43%, 81% and 93%, respectively.

The test was also consistent between the training and validation sets in its ability to identify the tissue where cancer had originated, with an accuracy of 93% in the validation set.

Dr Seiden said: "These data support the ability of this targeted methylation test to meet what we believe are the fundamental requirements for a multi-cancer early detection blood test that could be used for population-level screening: the ability to detect multiple deadly cancer types with a single test that has a very low false positive rate, and the ability to identify where in the body the cancer is located with high accuracy to help healthcare providers to direct next steps for diagnosis and care.

"Considering the burden of cancer in our society, it is important that we continue to explore the possibility that this test might intercept cancers at an earlier stage and, by extension, potentially reduce deaths from cancers for which screening is either not available or has poor adherence. To our knowledge, this is the largest clinical genomics study, in participants with and without cancer, to develop and validate a blood test for early detection of multiple cancers."

The study is funded by GRAIL, the maker of the blood test. Researchers are continuing to validate the test in large, prospective studies in the USA (STRIVE and PATHFINDER studies) and the UK (SUMMIT study), and to examine its feasibility for screening populations [2].

A strength of the CCGA study is that it includes more than 15,000 participants from 142 clinics in North America, ensuring results are generalisable to a diverse population. The ongoing studies are assessing the test's performance in even broader populations. Limitations include: all the participants with cancer had already been diagnosed with cancer (e.g. via screening or patients presenting with symptoms); the study was not designed to establish the test's impact on death from cancer or other causes; at the time of this analysis, not all patients had been followed for a year, which is needed to ensure their non-cancer status was accurate; and some inaccuracy occurred in the detection of the tissue of origin for cancers that are driven by the human papilloma virus (HPV), such as cancers of the cervix, anus, and head and neck - this information is being used to improve the test's performance.

Editor-in-chief of Annals of Oncology, Professor Fabrice André, Director of Research at the Institute Gustave Roussy, Villejuif, France, said: "This is a landmark study and a first step toward the development of easy-to-perform screening tools. Earlier detection of more than 50% of cancers could save millions of lives every year worldwide and could dramatically reduce morbidity induced by aggressive treatments.

"While numbers are still small, the performance of this new technology is particularly intriguing in pancreatic cancer, for which mortality rates are very high because it is usually diagnosed when it's at an advanced stage."

This is only for your information, kindly take the advice of your doctor for medicines, exercises and so on.     

https://gscrochetdesigns.blogspot.com. one can see my crochet creations  
https://gseasyrecipes.blogspot.com. feel free to view for easy, simple and healthy recipes    
https://kneereplacement-stickclub.blogspot.com. for info on knee replacement